Vancouver-based
Ketamine One Capital Limited (NEO: MEDI, Forum) announced on Wednesday that it had recently entered into a non-binding letter of intent to enter into an arranged partnership with
Illumma LLC, a ketamine infusion practice operating in Texas.
For an estimated
$980,000, Ketamine One’s Interim CEO said in a news release that this acquisition will significantly grow MEDI’s offering of clinics to prospective patients in the United States.
“Through Dr. Ken Adolph’s leadership, Illumma’s two existing clinics have already contributed to the improved mental health of their patients by applying innovative ketamine infusion therapies like those offered in Ketamine One’s clinical network. We expect that this arrangement will attract other partnerships or even acquisition targets and yield further expansion opportunities across the United States.”
Focused on consolidating medical clinics and becoming a North American leader in mental health treatments, Ketamine One has a network of 16 clinics across North America. The recent addition of
KGK Science Inc. as the company’s contract research division also places the company at the premium clinical research space.